Sphera Funds Management’s Teva Pharmaceuticals TEVA Stock Holding History

Sphera Funds Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-210,000	Closed	-$1.97M	–	81
2022 Q1	$1.97M	Buy	+210,000	New	+$1.75M	0.28%	55
2017 Q4	–	Sell	-72,000	Closed	-$1.27M	–	150
2017 Q3	$1.27M	Buy	72,000 +70,880	+6,329%	+$1.59M	0.18%	98
2017 Q2	$3.6M	Buy	+1,120	New	+$34.7K	0.61%	50
2014 Q3	–	Sell	-1,000	Closed	-$80K	–	143
2014 Q2	$80K	Buy	+1,000	New	+$51.1K	0.02%	94

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Sphera Funds Management's TEVA Position: Q2 2026 in Review

Sphera Funds Management increased its Teva Pharmaceuticals (TEVA) stake by 32% in Q2 2026, buying an estimated $12.1M and bringing the position to 1,500,082 shares worth $50.8M. The position accounts for 6.63% of the portfolio, ranked #1.

Sphera Funds Management first reported a position in TEVA in Q4 2013 and has held it in 46 quarters since. The position peaked at $51.5M in Q4 2015. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Sphera Funds Management held 1,500,082 shares of Teva Pharmaceuticals worth $50.8M as of Q2 2026.
Sphera Funds Management bought 363,107 Teva Pharmaceuticals shares in Q2 2026, an estimated $12.1M.
Teva Pharmaceuticals made up 6.63% of Sphera Funds Management's portfolio in Q2 2026, its #1 holding.
Sphera Funds Management first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 46 quarters since.
Sphera Funds Management's Teva Pharmaceuticals position peaked at $51.5M in Q4 2015.
675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.